Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 319

1.

Mediators of Inflammation-Driven Expansion, Trafficking, and Function of Tumor-Infiltrating MDSCs.

Tannenbaum CS, Rayman PA, Pavicic PG, Kim JS, Wei W, Polefko A, Wallace W, Rini BI, Morris-Stiff G, Allende DS, Hamilton T, Finke JH, Diaz-Montero CM.

Cancer Immunol Res. 2019 Oct;7(10):1687-1699. doi: 10.1158/2326-6066.CIR-18-0578. Epub 2019 Aug 22.

PMID:
31439615
2.

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.

Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI.

Lancet Oncol. 2019 Oct;20(10):1386-1394. doi: 10.1016/S1470-2045(19)30513-3. Epub 2019 Aug 16.

PMID:
31427205
3.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators.

Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16. Erratum in: Lancet Oncol. 2019 Aug 21;:.

PMID:
31427204
4.

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B.

Eur Urol Oncol. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. Epub 2019 Aug 1. Review.

PMID:
31377308
5.

Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply.

Rini BI, Powles T.

N Engl J Med. 2019 Jun 27;380(26):2582. doi: 10.1056/NEJMc1905518. No abstract available.

PMID:
31242371
6.

Adjuvant therapy in renal cell carcinoma.

Gul A, Rini BI.

Cancer. 2019 Sep 1;125(17):2935-2944. doi: 10.1002/cncr.32144. Epub 2019 Jun 21. Review.

PMID:
31225907
7.

Immunotherapy for renal cell carcinoma.

Sheng IY, Rini BI.

Expert Opin Biol Ther. 2019 Sep;19(9):897-905. doi: 10.1080/14712598.2019.1628946. Epub 2019 Jun 12.

PMID:
31173514
8.

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.

Ornstein MC, Wood LS, Hobbs BP, Allman KD, Martin A, Bevan M, Gilligan TD, Garcia JA, Rini BI.

J Immunother Cancer. 2019 May 16;7(1):127. doi: 10.1186/s40425-019-0615-z.

9.

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL, Hawkins R, Ravaud A, Alekseev B, Staehler M, Uemura M, De Giorgi U, Mellado B, Porta C, Melichar B, Gurney H, Bedke J, Choueiri TK, Parnis F, Khaznadar T, Thobhani A, Li S, Piault-Louis E, Frantz G, Huseni M, Schiff C, Green MC, Motzer RJ; IMmotion151 Study Group.

Lancet. 2019 Jun 15;393(10189):2404-2415. doi: 10.1016/S0140-6736(19)30723-8. Epub 2019 May 9.

PMID:
31079938
10.

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

Voss MH, Bhatt RS, Vogelzang NJ, Fishman M, Alter RS, Rini BI, Beck JT, Joshi M, Hauke R, Atkins MB, Burgess E, Logan TF, Shaffer D, Parikh R, Moazzam N, Zhang X, Glasser C, Sherman ML, Plimack ER.

Cancer. 2019 Jul 15;125(14):2400-2408. doi: 10.1002/cncr.32061. Epub 2019 Apr 5.

PMID:
30951193
11.

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2019 Mar 14;7(1):73. doi: 10.1186/s40425-019-0559-3.

12.

Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.

Ornstein MC, Calabrese C, Wood LS, Kirchner E, Profusek P, Allman KD, Martin A, Kontzias A, Grivas P, Garcia JA, Calabrese LH, Rini BI.

Clin Genitourin Cancer. 2019 Jun;17(3):177-182. doi: 10.1016/j.clgc.2019.01.021. Epub 2019 Feb 7.

PMID:
30824360
13.

Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis.

Field CA, Cotta BH, Jimenez J, Lane BR, Yim K, Lee HJ, Ryan ST, Hamilton ZA, Patel S, Wang S, Kane CJ, Dey S, Mckay RR, Noyes S, Millard FE, Rini BI, Campbell SC, Derweesh IH.

Clin Genitourin Cancer. 2019 Jun;17(3):e505-e512. doi: 10.1016/j.clgc.2019.01.013. Epub 2019 Jan 30.

PMID:
30808547
14.

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T; KEYNOTE-426 Investigators.

N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16.

PMID:
30779529
15.

HIF Inhibitors: Status of Current Clinical Development.

Fallah J, Rini BI.

Curr Oncol Rep. 2019 Jan 22;21(1):6. doi: 10.1007/s11912-019-0752-z. Review.

PMID:
30671662
16.

Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.

Cella D, Grünwald V, Escudier B, Hammers HJ, George S, Nathan P, Grimm MO, Rini BI, Doan J, Ivanescu C, Paty J, Mekan S, Motzer RJ.

Lancet Oncol. 2019 Feb;20(2):297-310. doi: 10.1016/S1470-2045(18)30778-2. Epub 2019 Jan 15. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

PMID:
30658932
17.

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study.

Tomita Y, Uemura H, Oya M, Shinohara N, Habuchi T, Fujii Y, Kamei Y, Umeyama Y, Bair AH, Rini BI.

BMC Cancer. 2019 Jan 7;19(1):17. doi: 10.1186/s12885-018-5224-6.

18.

Radical shifts in the first-line management of metastatic renal cell carcinoma.

Ornstein MC, Rini BI.

Nat Rev Clin Oncol. 2019 Feb;16(2):71-72. doi: 10.1038/s41571-018-0146-4. No abstract available.

PMID:
30538304
19.

Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma.

Cella D, Motzer RJ, Rini BI, Cappelleri JC, Ramaswamy K, Hariharan S, Arondekar B, Bushmakin AG.

Value Health. 2018 Dec;21(12):1413-1418. doi: 10.1016/j.jval.2018.04.1371. Epub 2018 May 11.

PMID:
30502785
20.

Emerging Role of Combination Immunotherapy in the First-line Treatment of Advanced Renal Cell Carcinoma: A Review.

George S, Rini BI, Hammers HJ.

JAMA Oncol. 2019 Mar 1;5(3):411-421. doi: 10.1001/jamaoncol.2018.4604.

PMID:
30476955
21.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0. Erratum in: J Immunother Cancer. 2019 Mar 14;7(1):73.

22.

Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies.

Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stühler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY.

Clin Genitourin Cancer. 2019 Feb;17(1):65-71. doi: 10.1016/j.clgc.2018.09.006. Epub 2018 Sep 12.

PMID:
30341028
23.

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.

Zahoor H, Barata PC, Jia X, Martin A, Allman KD, Wood LS, Gilligan TD, Grivas P, Ornstein MC, Garcia JA, Rini BI.

J Immunother Cancer. 2018 Oct 17;6(1):107. doi: 10.1186/s40425-018-0425-8.

24.

Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.

Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P.

Clin Cancer Res. 2019 Jan 1;25(1):210-221. doi: 10.1158/1078-0432.CCR-18-1278. Epub 2018 Oct 16.

25.

Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T, Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC.

Cancer. 2018 Sep 15;124(18):3677-3683. doi: 10.1002/cncr.31595. Epub 2018 Oct 11.

26.

Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0235-z.

PMID:
30291359
27.

Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.

Tzeng A, Diaz-Montero CM, Rayman PA, Kim JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S, Schach K, Emamekhoo H, Ernstoff MS, Hoimes CJ, Rini BI, Garcia JA, Gilligan TD, Ornstein MC, Grivas P.

Target Oncol. 2018 Oct;13(5):599-609. doi: 10.1007/s11523-018-0595-9.

PMID:
30267200
28.

Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery.

Almassi N, Gao T, Lee B, Stein RJ, Haber GP, Ornstein MC, Rini BI, Gilligan TD, Garcia JA, Stephenson AJ, Grivas P.

Clin Genitourin Cancer. 2018 Dec;16(6):e1237-e1242. doi: 10.1016/j.clgc.2018.08.003. Epub 2018 Aug 22.

PMID:
30217764
29.

Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma.

Zahoor H, Pavicic PG Jr, Przybycin C, Ko J, Stephens L, Radivoyevitch T, Jia X, Diaz-Montero CM, Finke J, Rayman PA, Gilligan TD, Grivas P, Ornstein M, Garcia JA, Rini BI.

Medicine (Baltimore). 2018 Sep;97(37):e12344. doi: 10.1097/MD.0000000000012344.

30.

Information Transparency in the Drug Approval Process.

Rini BI, Burstein HJ, George DJ.

JAMA Oncol. 2018 Nov 1;4(11):1621-1622. doi: 10.1001/jamaoncol.2018.4143. No abstract available.

PMID:
30193367
31.

Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma.

Barata PC, Mendiratta P, Kotecha R, Gopalakrishnan D, Juloori A, Chao ST, Koshkin V, Ornstein M, Gilligan TD, Wood LS, Rini BI, Angelov L, Garcia JA.

Clin Genitourin Cancer. 2018 Oct;16(5):413-419.e1. doi: 10.1016/j.clgc.2018.07.018. Epub 2018 Aug 17.

PMID:
30172552
32.

The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.

Chen YW, Ornstein MC, Wood LS, Allman KD, Martin A, Beach J, Gilligan T, Garcia JA, Rini BI.

Urol Oncol. 2018 Oct;36(10):470.e19-470.e29. doi: 10.1016/j.urolonc.2018.06.013. Epub 2018 Aug 18.

PMID:
30131292
33.

Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.

Barata P, Emamekhoo H, Mendiratta P, Koshkin V, Tyler A, Ornstein M, Rini BI, Gilligan T, Kyriakopoulos C, Garcia JA.

Prostate. 2018 Sep;78(13):1035-1041. doi: 10.1002/pros.23663. Epub 2018 Jun 7.

PMID:
29882332
34.

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, Sznol M, Hainsworth J, Rathmell WK, Stadler WM, Hutson T, Gore ME, Ravaud A, Bracarda S, Suárez C, Danielli R, Gruenwald V, Choueiri TK, Nickles D, Jhunjhunwala S, Piault-Louis E, Thobhani A, Qiu J, Chen DS, Hegde PS, Schiff C, Fine GD, Powles T.

Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4. Erratum in: Nat Med. 2018 Dec;24(12):1941.

35.

Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.

Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ.

Clin Genitourin Cancer. 2018 Aug;16(4):298-304. doi: 10.1016/j.clgc.2018.04.005. Epub 2018 May 4.

36.

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.

Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K, Tyler A, Martin A, Gilligan T, Grivas P, Ornstein M, Garcia JA, Powles T, Rini BI.

Br J Cancer. 2018 Jul;119(2):160-163. doi: 10.1038/s41416-018-0104-z. Epub 2018 May 24.

37.

Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib.

Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, Knezevic D, Goddard AD, Febbo PG, Li R, Lin X, Valota O, Staehler M, Motzer RJ, Ravaud A.

Clin Cancer Res. 2018 Sep 15;24(18):4407-4415. doi: 10.1158/1078-0432.CCR-18-0323. Epub 2018 May 17.

38.

Current and emerging first-line systemic therapies in clear cell renal cell carcinoma.

Rini BI.

Clin Adv Hematol Oncol. 2018 Feb;16(2):115-117. No abstract available.

PMID:
29741511
39.

Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.

Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI.

J Clin Oncol. 2018 Jun 1;36(16):1588-1593. doi: 10.1200/JCO.2017.77.1485. Epub 2018 Apr 11.

40.

Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies.

Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P.

Target Oncol. 2018 Jun;13(3):353-361. doi: 10.1007/s11523-018-0561-6.

PMID:
29623487
41.

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.

Ornstein MC, Diaz-Montero CM, Rayman P, Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M, Devonshire S, Dann P, Schach K, Stephenson A, Campbell S, Emamekhoo H, Ernstoff MS, Hoimes CJ, Gilligan TD, Rini BI, Garcia JA, Grivas P.

Urol Oncol. 2018 Sep;36(9):405-412. doi: 10.1016/j.urolonc.2018.02.018. Epub 2018 Mar 30. Review.

PMID:
29606341
42.

Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more.

Zahoor H, Rini BI, Ornstein MC.

Oncotarget. 2017 Dec 6;9(18):14036-14037. doi: 10.18632/oncotarget.23005. eCollection 2018 Mar 6. No abstract available.

43.

Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.

Koshkin VS, Barata PC, Rybicki LA, Zahoor H, Almassi N, Redden AM, Fergany AF, Kaouk J, Haber GP, Stephenson AJ, Ornstein MC, Gilligan T, Garcia JA, Rini BI, Grivas P.

Clin Genitourin Cancer. 2018 Aug;16(4):e879-e892. doi: 10.1016/j.clgc.2018.02.002. Epub 2018 Feb 22.

PMID:
29576445
44.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators.

N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.

45.

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.

Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI.

Lancet Oncol. 2018 Apr;19(4):451-460. doi: 10.1016/S1470-2045(18)30107-4. Epub 2018 Mar 9.

PMID:
29530667
46.

Goldilocks Dosing of TKIs: A Dose that Is Just Right Leads to Optimal Outcomes.

Rini BI.

Clin Cancer Res. 2018 Jul 1;24(13):2979-2980. doi: 10.1158/1078-0432.CCR-18-0291. Epub 2018 Mar 9.

47.

A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma.

Liu X, Swen JJ, Diekstra MHM, Boven E, Castellano D, Gelderblom H, Mathijssen RHJ, Vermeulen SH, Oosterwijk E, Junker K, Roessler M, Alexiusdottir K, Sverrisdottir A, Radu MT, Ambert V, Eisen T, Warren A, Rodríguez-Antona C, García-Donas J, Böhringer S, Koudijs KKM, Kiemeney LALM, Rini BI, Guchelaar HJ.

Clin Cancer Res. 2018 May 15;24(10):2350-2356. doi: 10.1158/1078-0432.CCR-17-2815. Epub 2018 Feb 28.

48.

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI.

J Immunother Cancer. 2018 Jan 29;6(1):9. doi: 10.1186/s40425-018-0319-9.

49.

Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.

Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK.

J Clin Oncol. 2018 Mar 20;36(9):867-874. doi: 10.1200/JCO.2017.74.2627. Epub 2017 Dec 19.

50.

Organ Preservation for Recurrent Urethral Adenocarcinoma With Concurrent Chemotherapy and Radiation.

Mendiratta P, Rini BI, Tendulkar RD.

Urology. 2018 Mar;113:e1-e2. doi: 10.1016/j.urology.2017.11.033. Epub 2017 Dec 2.

PMID:
29203190

Supplemental Content

Loading ...
Support Center